PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

被引：0
|
作者：
Sabbatino, Francesco [1 ]
Wang, Yangyang [1 ]
Wang, Xinhui [1 ]
Flaherty, Keith T. [1 ]
Pepin, David [1 ]
Scognamiglio, Giosue [2 ]
Yu, Ling [3 ]
Cooper, Zachary A. [4 ]
Pepe, Stefano [5 ]
Kirkwood, John M. [6 ]
Frederick, Dennie T. [1 ]
Wargo, Jennifer A. [4 ]
Ferrone, Soldano [1 ]
Ferrone, Cristina R. [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[2] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
[3] Southwest Univ, Inst Clean Energy & Adv Mat, Chongqing, Peoples R China
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Salerno, I-84100 Salerno, Italy
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3703
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A dual mechanism of activation of the sonic hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma
    Parascandolo, Alessia
    Laukkanen, Mikko O.
    De Rosa, Nancy
    Ugolini, Clara
    Cantisani, Maria Carmela
    Cirafici, Anna Maria
    Basolo, Fulvio
    Santoro, Massimo
    Castellone, Maria Domenica
    ONCOTARGET, 2018, 9 (04) : 4496 - 4510
  • [32] PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
    Tutuka, Candani S. A.
    Andrews, Miles C.
    Mariadason, John M.
    Ioannidis, Paul
    Hudson, Christopher
    Cebon, Jonathan
    Behren, Andreas
    MOLECULAR CANCER, 2017, 16
  • [33] PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
    Candani S. A. Tutuka
    Miles C. Andrews
    John M. Mariadason
    Paul Ioannidis
    Christopher Hudson
    Jonathan Cebon
    Andreas Behren
    Molecular Cancer, 16
  • [34] The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma
    Filitis, Dan C.
    Rauh, Jake
    Mahalingam, Meera
    MELANOMA RESEARCH, 2015, 25 (06) : 470 - 478
  • [35] Pou4f1 promotes braf inhibitor resistance by reactivating mapk signaling pathway in melanoma
    Liu, L.
    Yue, Q.
    Ma, J.
    Shi, Q.
    Li, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S140 - S140
  • [36] The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells
    Guerriero, Luana
    Palmieri, Giuseppe
    De Marco, Margot
    Cossu, Antonio
    Remondelli, Paolo
    Capunzo, Mario
    Turco, Maria Caterina
    Rosati, Alessandra
    ONCOTARGET, 2017, 8 (46) : 80393 - 80404
  • [37] Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells
    Zhu, G.
    Li, C.
    Gao, T.
    Guo, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S214 - S214
  • [38] Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells
    Guo, Sen
    Yue, Qiao
    Wang, Shiyu
    Wang, Huina
    Ye, Zhubiao
    Zhang, Weigang
    Shi, Qiong
    Gao, Tianwen
    Li, Chunying
    Zhu, Guannan
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2023, 109 (02) : 52 - 60
  • [39] BRAF and GNAQ mutation cellular effects in mTOR pathway activation in human cells (BRAF mutational status is a candidate biomarker for response to mTOR inhibitors therapy)
    Vinagre, J.
    Populo, H.
    Faustino, A.
    Tavares, S.
    Lopes, J. M.
    Soares, P.
    VIRCHOWS ARCHIV, 2011, 459 : S43 - S43
  • [40] Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells
    Ross, Kayleigh C.
    Andrews, Andrew J.
    Marion, Christopher D.
    Yen, Timothy J.
    Bhattacharjee, Vikram
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1596 - 1609
12345